To investigate the mechanism underlying the improved anti-tumor efficacy of mAWT020 compared to αmPD1, CT26 tumor-bearing mice were treated with 1 mg/kg of αmPD1, 1 mg/kg of αmPD1-IL-2x, or 1 mg/kg of mAWT020 (biw) to compare the immune subset profile in blood and tumor. Here, AMPD1 is linked to neoplasm.